Home Blog Page 1375

Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience

By
Advertorial Desk
-

SINGAPORE, Jan. 15, 2026 /PRNewswire/ — Today, Visa, a world leader in digital payments, announced its support for Chinese Visa cardholders to pay with Apple Pay. Together with Apple, Visa will enable Chinese cardholders to add Visa cards[1] from participating banks to Apple Pay and make payments at overseas Visa-accepting merchants, in-store, in-app and online. Today, 79 percent[2] of in-person transactions globally are made contactlessly with NFC.

Yin Xiaolong, General Manager at Visa Mainland China, said: “As global digital payments develop rapidly, consumers increasingly expect mobile payment solutions that are smartphone-based and interoperable. Visa has long been committed to providing Chinese cardholders with diverse payment options, enabling them to enjoy a secure and seamless payment experience wherever they are. Upholding our long‑standing commitment to the Chinese market and to our cardholders, Visa is increasing its investments in data and payment security, launching tokenization services and taking the lead in enabling their use in cross‑border scenarios. We are delighted to work with Apple and financial institutions to bring Chinese cardholders a safer and more convenient new mobile payment experience.”

The first batch of supporting issuing banks includes Industrial and Commercial Bank of China, Bank of China, Agricultural Bank of China, Bank of Communications, China Merchants Bank, China CITIC Bank, Ping An Bank and Industrial Bank. Visa and Apple are working closely with more banking partners, including Shanghai Pudong Development Bank, China Construction Bank, China Minsheng Bank and China Everbright Bank, and related features will be rolled out in the future.

Easy Payments Online and Offline

When using Apple Pay for in-store payments, consumers simply double-click the side button, authenticate, and hold their iPhone or Apple Watch near the payment terminal for contactless payment. Every Apple Pay transaction requires secure authentication using Face ID, Touch ID, or device passcode, and the result is sent to the issuing bank as a one-time dynamic security transaction code, putting transaction security firmly in the hands of the consumer.

Consumers can also use Apple Pay on iPhone and iPad for faster, more convenient payments in overseas mobile apps or online websites, without the need to create accounts or repeatedly entering contact information, card numbers, shipping, and billing details.

Built-in Privacy and Security Protection

Security and privacy are at the core of Apple Pay. When adding Visa cards, the actual card number is neither stored on the device nor on Apple’s servers. Instead, the system assigns a unique Device Account Number generated using Visa’s tokenization technology, encrypts it, and stores it securely in the device’s Secure Element. This is an industry-standard certified chip designed specifically to securely store payment information on the device.

Quick Setup, Easy to add  Visa Cards

Setting up Apple Pay is simple. Open the Wallet app on your iPhone, tap the plus sign, then follow the prompts to navigate to your bank’s app and add your Visa card, or add your Visa card directly to Apple Wallet via your bank’s app. Once the card is added to your iPhone, Apple Watch, or iPad, you can immediately start using Apple Pay on that device.

Cardholders continue to enjoy the same rewards and benefits as with their physical cards. In addition, Visa has launched exclusive offers such as first-time binding bonuses and transportation perks, covering travel abroad and overseas living scenarios. Cardholders can visit the Visa “V Select” WeChat Mini Program for more information on benefits.

For more information about Visa, please visit: www.visa.cn/pay-with-visa/featured-technologies/applepay.html

For more information about Apple Pay, please visit: https://www.apple.com/cn/apple-pay/

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.cn.

[1]The first batch of supporting issuing banks includes Industrial and Commercial Bank of China (credit card), Bank of China (credit card), Agricultural Bank of China (credit card), Bank of Communications (credit card), China Merchants Bank (credit card), China CITIC Bank (credit and debit card), Ping An Bank (credit) and Industrial Bank (credit card).

[2] Visa’s 2025 Annual Report: s29.q4cdn.com/385744025/files/doc_downloads/2025/Visa-Fiscal-2025-Annual-Report.pdf

 

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

By
Advertorial Desk
-

SHANGHAI, Jan. 15, 2026 /PRNewswire/ — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting its first patient in early 2026 [1].

In September 2024, Belief BioMed (BBM) and AskBio entered astrategic collaboration to explore the potential for new gene therapies [2]. BBM granted AskBio a sublicense to use the proprietary AAV capsid in the AB-1009 program and provided AAV vector production services. Within the collaborative development framework, BBM worked closely with the AskBio team, and its contributions were instrumental to the IND acceptance. 

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of Belief BioMed, said, “We are delighted to learn that our partner AskBio has received IND acceptance for its gene therapy. This marks a significant milestone in our strategic collaboration and represents a practical achievement in globalized innovation within the gene therapy field. On behalf of Belief BioMed, I extend our sincere congratulations to the AskBio team! This IND acceptance reflects AskBio’s outstanding R&D capabilities and efficient clinical advancement, while also demonstrating the strong synergy between our technological resources and platforms. Looking ahead, Belief BioMed hopes to deepen our collaboration with AskBio to accelerate the global development of innovative therapies.”

About Pompe Disease

Pompe disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. The disease can be debilitating and is characterized by severe muscle weakness that worsens over time and is accompanied by diaphragmatic involvement, leading to respiratory insufficiency early in the course of the disease. Pompe disease ranges from a rapidly fatal infantile form with significant impacts to heart function, to a more slowly progressive, late-onset form primarily affecting skeletal muscle. It is estimated that Pompe disease affects approximately 5,000 to 10,000 people worldwide.

References

1. https://www.askbio.com/
2. https://www.beliefbiomed.com/newsd-749.html 

About Belief BioMed

Belief BioMed Inc. (BBM) is a global biotech company that integrates the research and development, manufacturing and clinical application of gene therapy products. The company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology. BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production platform for gene therapy drugs. The company has been building up its capabilities in a variety of fields including novel AAV capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinically applicable vector manufacturing process. It has also established an extensive R&D pipeline covering a wide range of unmet clinical needs in different therapeutic areas such as hemophilia, DMD, Parkinson’s disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted IND filings. The Biologics License Application (BLA) of a gene therapy for the treatment of adult patients with hemophilia B, has been approved by the NMPA of China. For more information, visit www.beliefbiomed.com.

Statement

This information is only for the purpose of introducing the company’s event and information on that date, and is not intended to promote any company’s products and/or services, nor should it be construed as providing any advice or recommendation on the selection of any drugs, medical devices and treatment options.

For information about any company products, diseases and/or treatments, please consult a healthcare professional.

AB-1009 described herein has not been approved for marketing.

CLO Secures Final Victory in Software Copyright Infringement Case Against Style3D; Court Recognizes Large-Scale Commercial Piracy

By
Advertorial Desk
-

SHANGHAI, Jan. 15, 2026 /PRNewswire/ — CLO Virtual Fashion (“CLO”), a leading provider of 3D fashion technology and end-to-end digital solutions, today announced that it has obtained a final and binding judgment from the Zhejiang Provincial High People’s Court in a computer software copyright infringement lawsuit against Zhejiang Lingdi Digital Technology Co. Ltd. (“Linctex”), the company behind Style3D. This ruling brings closure to a multi-year legal dispute, providing robust judicial protection for CLO’s core intellectual property. It underscores China’s firm commitment to strengthening IP protection and improving the business environment, while setting a significant industry benchmark for fair competition.

According to the final judgment by the Zhejiang Provincial High People’s Court, after thorough examination, the court clearly established that Linctex engaged in willful infringement by “prolonged, large-scale, and frequent” use of cracked versions of CLO software in its commercial operations. This activity directly infringed upon CLO’s legally protected computer software copyright. The court lawfully dismissed Linctex’s “fair use” defense, clarifying that the use had a direct commercial purpose. The judgment is now legally effective, providing final and comprehensive judicial protection for CLO’s legitimate rights and interests.

“We sincerely respect and thank the Chinese judicial authorities affirming the severity of the violations. This outcome fully reflects the importance China places on intellectual property protection. It sends a crucial signal to the entire industry about respecting and adhering to the rules, and it strengthens our convictions about deepening our commitment to the Chinese market,” said Simon Kim, CEO of CLO Virtual Fashion. “We pursued this case to protect not only our own innovations but the stability of the entire digital fashion ecosystem. Brands and companies need to know that the tools they rely on are stable, secure, and built on sound foundations.”

Kim further emphasized, “CLO’s commitment to the Chinese market is long-term and steadfast. Moving forward, we will continue to empower the digital transformation of China’s fashion industry through localized product development, responsive technical support, and deep collaboration with ecosystem partners.”

Linctex has been ordered to immediately cease all infringing activities and compensate CLO. CLO remains committed to its global anti-piracy efforts, ensuring a fair, competitive, and secure environment for all creators and enterprises in the digital fashion space.

About CLO Virtual Fashion

Evolved from the word “clothing”, CLO Virtual Fashion has been transforming and innovating the way people communicate and consume fashion since its launch in 2009. With more than 15 years of research and development in garment simulation, the company is leading the market by digitally merging, consolidating, and converging all components related to digital garments through its state-of-the-art 3D Cloth Simulation Algorithm. From 3D garment design software, digital asset management and design development collaborative platforms, all of CLO Virtual Fashion’s products and services are interconnected to provide clients and users with a more consolidated experience.

 

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

By
Advertorial Desk
-
  • Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
  • 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
  • Complex modalities are WuXi Biologics’ core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs
  • Bispecific/multispecific antibodies are WuXi Biologics’ most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company’s revenue and delivers 120%+ YoY growth
  • Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East

SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company’s 2025 achievements and outlining its outlook.

Dr. Chen commented, “Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our ‘Follow and Win the Molecule’ strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution.”

Strong Project Funnel Achieving Record High

Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total to 945 and reinforcing its position as the partner of choice for biopharma innovators worldwide. Approximately half of the new projects originated from U.S. clients, underscoring strong client trust from the market. 

The company has excelled in three key areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities.

Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively. Together, these complex modalities now account for nearly 50% of the total pipeline, underscoring strong demand for differentiated biologics. In parallel, the company maintains a deep and diversified base of over 400 mAbs and other protein therapeutics, including multiple multi-billion-dollar franchises in late-stage development and commercial manufacturing. With strength across research, development, manufacturing, bispecific/multispecific antibodies represent WuXi Biologics’ most exciting, fastest-growing and highest‑margin modality, contributing nearly 20% of the company’s revenue and achieving YoY growth exceeding 120%.

Through its “Win-the-Molecule” strategy, WuXi Biologics has been securing a quantity of projects across different stages. In 2025, the company added 23 projects, including 6 Phase III and commercial projects. Notably, half of these projects involve complex modalities, led by bispecific/multispecific antibodies and ADCs.

Research: Accelerating Deal Momentum and Platform Inflection

Research services maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company’s CD3 platform.

The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab.

WuXi Biologics’ research services business achieved another record year in 2025, securing record-breaking upfront payments and potential milestone values exceeding USD 4 billion.

Development: Pioneering Innovative Solutions

WuXi Biologics continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing.

It launched WuXia™ TrueSite, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. The platform has achieved an average mAb titer exceeding 8.0 g/L, with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations.

The company has also expanded core technology solutions for high-dose delivery into clinical and commercial applications, including High-throughput formulation development platform WuXiHighTM, Hyaluronidase Co-Formulation platform, and large-volume devices capabilities.

Manufacturing: Advancing Growth at Speed and Scale

As the “Follow and Win the Molecule” strategy continues, the total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025. Manufacturing is positioned for accelerated growth, driven by an expanding commercial portfolio and revenue ramp per program over time.

Built on operational excellence, technology leadership and a proven quality system, WuXi Biologics completed 28 PPQs in 2025 and has 34 PPQs scheduled for 2026 based on current contracts, reflecting strong momentum in CMO services. It has achieved a 99%+ success rate on PPQ batches, ranking among the industry’s top performers. Since 2017, it has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners.

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry’s rigorous quality standards. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics passed more than 1,800 GMP quality audits led by clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients’ trust.

Global Layout: Building Strategic Hubs in the U.S., Singapore and Qatar

WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging cross‑site synergies among facilities in New Jersey and Massachusetts, the company enables the seamless transfer of materials, samples, and products across the U.S..

In Singapore, the company has commenced construction of its new modular drug product facility, while the drug substance modular facility is currently in the design phase. Meanwhile, its subsidiary WuXi XDC achieved mechanical completion of its Singapore manufacturing facility in June 2025, positioning the Singapore site as a strategic hub within the global network.

In December 2025, WuXi Biologics announced the signing of an MOU with the Qatar Free Zones Authority (QFZ). The long-term strategy is to establish the Qatar site as a strategic pillar within WuXi Biologics’ global CRDMO network, marking the company’s entry into the region while extending its global footprint and capabilities.

Global Leading Digital CRDMO: Powering World-class Speed, Quality, Operational Efficiency and Client Experience

WuXi Biologics has embedded digital innovations into every fabric of research, development, manufacturing, operations and customer engagement that truly redefined values for its partners.

The DaVinci Client Portal provides a secure, real-time interface for proposal generation, access to experimental and manufacturing data and reports, cost estimates, and shipment tracking. Lab core systems, such as BioFoundry and InSilico, accelerate discovery, development and manufacturing by enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLabTM to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.

A Leader in Industry Sustainability

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics has made significant strides in sustainability, earning widespread industry recognition. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP “A List” for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

Sustainable High Growth in 2026

In 2026, WuXi Biologics will build on strong momentum with accelerated growth driven by robust research, leading development and explosive manufacturing business. By putting clients first and leveraging its full end‑to‑end capabilities, WuXi Biologics is fast‑tracking biologics innovation for global clients and delivering meaningful benefits to patients around the world.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Business
info@wuxibiologics.com

 

US Suspends Immigrant Visa Processing for 75 Countries, Thailand, Cambodia on the List

By
Laotian Times
-
This photo is used for representational purpose only.

AFP – The United States said on 14 January it was suspending the processing of immigrant visas from 75 countries, President Donald Trump’s latest move against foreigners seeking to come to America.

The United States has long rejected visas from people who appear likely to end up needing government welfare, but the State Department said it would now use the same authority for a blanket suspension of immigrant visas based on nationality.

“The Trump administration is bringing an end to the abuse of America’s immigration system by those who would extract wealth from the American people,” State Department spokesman Tommy Pigott said.

“Immigrant visa processing from these 75 countries will be paused while the State Department reassesses immigration processing procedures to prevent the entry of foreign nationals who would take welfare and public benefits,” he said.

White House Press Secretary Karoline Leavitt posted on X that the countries affected would include Somalia, whose people Trump has attacked in heated terms after immigrants were involved in a funding scandal in Minnesota, as well as Russia and Iran.

A US official said that the other countries affected would include a number of countries with friendly relations with the United States, including Brazil, Egypt and Thailand.

Other countries to face the pause include Nigeria, Africa’s most populous country, as well as Iraq and Yemen, the official said.

The State Department did not immediately release a full list of countries.

The freeze will begin on 21 January with no set time for it to end, the US official, who was not authorized to speak to the press, said on condition of anonymity.

Trump has made no secret of his desire to reduce immigration by people who are not of European descent. He has described Somalis as “garbage” who should “go back to where they came from” and instead said he was open to Scandinavians moving to the United States.

The State Department said Monday that it has revoked more than 100,000 visas since Trump’s return, a one-year record.

The Department of Homeland Security last month said that the Trump administration has deported more than 605,000 people, and that 2.5 million others left on their own.

The latest move does not affect tourist, business or other visas, including for soccer fans seeking to visit for this year’s World Cup, although the Trump administration has vowed to vet all applicants’ social media histories.

© Agence France-Presse

Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus

By
Advertorial Desk
-

– UCSD’s Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses ‘Xafty’ as “The weapon to end the virus war.” 
– Announces “One Drug, Two Tracks” strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. 
– Dr. Davey Smith: “With this multi-virus treatment, 2026 may mark the inaugural year of modern treatments that can treat multiple viruses with one drug, perhaps even viruses that haven’t hit us yet.”

SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — Hyundai Bioscience (KOSDAQ: 048410) today announced a groundbreaking roadmap to combat global viral epidemics, officially declaring its entry into Phase 2 clinical trials in the United States.

Presenting at the Biotech Showcase 2026, the company unveiled its pre-emptive therapeutic strategy using Xafty™, a broad-spectrum antiviral drug. The presentation highlighted a bold transition: “Preparation in Vietnam is complete. Now, it is America.”

– Dr. Davey Smith: “The Broad-Spectrum Weapon We Have Been Waiting For.”

The core of the announcement centered on the clinical strategy designed in collaboration with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD).

Dr. Smith, a world-renowned expert who previously led the U.S. government’s ACTIV-2 COVID-19 trials, diagnosed the current U.S. healthcare crisis as a “tripledemic” of Influenza, RSV, and COVID-19 variants, for which there is no unified countermeasure.

In a statement regarding the new clinical design, Dr. Smith emphasized, “We now have a promising weapon to fight multiple viruses at the same time. Xafty’s ‘Basket Trial’ design is the only efficient way to solve this multi-viral crisis.” He further urged, “There is no time to lose. We must proceed with the trials necessary with maximum speed to deliver this solution to patients who are currently defenseless.”

– “One Drug, Two Tracks”: A Universal Solution

Hyundai Bioscience presented its unique “One Drug, Two Tracks” global strategy. The company is using the same drug (Xafty) to target:

* Dengue Fever in Vietnam (Track 1)

* Upper-Respiratory Infection Viruses in the US (Track 2)

This approach validates the drug’s breadth and potency, demonstrating its potential to treat both mosquito-borne and respiratory viral infections. This mechanism is analogous to modern antibiotics that can treat multiple bacterial types with a single drug.

Mr. Jason Kim, CEO of Hyundai Bioscience USA, stated, “At the showcase, we confirmed that our strategy, designed with Dr. Smith, perfectly aligns with the unmet needs of the U.S. medical field. Our preparation is complete. We are ready to submit our IND application to the FDA immediately.”

– Vision: “2026, The Inaugural Year of a Virus-Free Era”

The announcement concluded with a historic vision for global public health, articulated by Dr. Smith. “For too long, we have been chasing after variants,” Dr. Smith noted. “But with this pre-emptive, broad-spectrum approach, we are finally getting ahead of the curve. I am confident that this trial will be a turning point for modern antivirals that can tackle multiple viruses with one drug.”

About Hyundai Bioscience:

Hyundai Bioscience is a biotechnology company focused on developing novel drug delivery systems (DDS) to repurpose existing drugs for new therapeutic applications. The company is a member of the US Medical CBRN Defense Consortium (MCDC). Its lead candidate, Xafty (CP-COV03), is an oral antiviral drug based on niclosamide, modified for enhanced bioavailability.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update these statements except as required by law.

Media Contact:
Jason Kim
gbd@hyundaibio.com
(562)964-3910

“Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show” Proudly Supported by Manulife

By
Advertorial Desk
-

HONG KONG and MACAU, Jan. 15, 2026 /PRNewswire/ — Manulife Hong Kong and Macau (“Manulife”) is proud to support “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show,” underscoring its commitment to mental well-being as an essential pillar of holistic health and spreading joy across the community by bringing people together through laughter and shared experiences. The occasion is especially meaningful as Manulife celebrates 30 years of serving the Macau community with trusted financial solutions and guidance, alongside its ongoing dedication to promoting emotional wellness.

Manulife Hong Kong and Macau is proud to support "Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show"
Manulife Hong Kong and Macau is proud to support “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show”

The show offers a fresh entertainment experience featuring international film star and stand-up comedy icon Jimmy O. Yang. Audiences can look forward to a vibrant mix of stand-up comedy, live performances, and guest engagement, complemented by special guest appearances from Jackson Wang, Tyson Yoshi and Wan Kwong — each bringing their own flair to create a festive and unforgettable event.

Event Details:
Dates & Times: February 21, 2026 (Saturday) at 8:00 PM and February 22, 2026 (Sunday) at 6:00 PM
Venue: Galaxy Arena
Ticket Prices: HKD/MOP 880 / 780 / 680 / 480 / 380
Language: Primarily in English, with occasional Cantonese and Mandarin

“As we celebrate 30 years in Macau, we are excited to support an event that fosters emotional connection and brings people together,” said Celia Ling, Chief Marketing Officer of Manulife Hong Kong and Macau. “We believe true well-being goes beyond financial security – it encompasses physical wellness and mental health. By supporting this event, we hope to create meaningful experiences for customers and inspire families to embrace a holistic approach to living well.”

Manulife continues to empower people to make decisions easier and lives better, helping communities thrive through innovative solutions and strong partnerships. This commitment to the community is reflected by our enduring presence in Macau, soon to be symbolized by the renaming of our Macau office building to Manulife Plaza. 

For more information about “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show”, please visit https://www.manulife.com.mo/en/individual/promotions/jimmy-o-yang-show.html.

About Manulife Hong Kong and Macau

Manulife Hong Kong has been a trusted name for more than 125 years, while we have served the Macau market for nearly three decades. Since our operations began in Asia in 1897, we have grown into one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.

Manulife Hong Kong and Macau, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.

About Manulife

Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong.

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.

YTL Cement’s CDL Academy and Universiti Teknologi Malaysia Sign MoU to Advance Talent Development and Research Innovation in Sustainable Construction

By
Advertorial Desk
-

PETALING JAYA, MALAYSIA – Media OutReach Newswire – 15 January 2026 – CDL Academy Sdn. Bhd. (CDL Academy), the learning and development arm of YTL Cement Group, and Universiti Teknologi Malaysia (UTM) have signed a Memorandum of Understanding (MoU) on 9 January 2026 to strengthen collaboration in talent development, applied learning, and sustainable construction practices for Malaysia’s engineering sector.

(from left to right): Datuk Aziyah Mohamed, Co-chairman of CDL Academy Sdn. Bhd., Dato’ Sr. Mohd Zaid Zakaria, Chairman of CDL Academy Sdn. Bhd., Prof. Dr. Mohd Shafry Bin Mohd Rahim, Vice-Chancellor of Universiti Teknologi Malaysia, and Associate Professor Ir. Dr. Noor Nabilah Sarbini, Director, Forensic Engineering Centre of Universiti Teknologi Malaysia during the Memorandum of Understanding signing ceremony between CDL Academy Sdn. Bhd. and Universiti Teknologi Malaysia.
(from left to right): Datuk Aziyah Mohamed, Co-chairman of CDL Academy Sdn. Bhd., Dato’ Sr. Mohd Zaid Zakaria, Chairman of CDL Academy Sdn. Bhd., Prof. Dr. Mohd Shafry Bin Mohd Rahim, Vice-Chancellor of Universiti Teknologi Malaysia, and Associate Professor Ir. Dr. Noor Nabilah Sarbini, Director, Forensic Engineering Centre of Universiti Teknologi Malaysia during the Memorandum of Understanding signing ceremony between CDL Academy Sdn. Bhd. and Universiti Teknologi Malaysia.

The MoU was signed by UTM Vice Chancellor Prof. Dr. Mohd Shafry Mohd Rahim and CDL Academy Chairman Dato’ Sr. Mohd Zaid Zakaria. It formalises the ongoing partnership between the two organisations and aims to provide students with industry exposure and practical experience, preparing them for careers in the construction sector.

Under the agreement, UTM and CDL Academy will pursue initiatives including professional training programmes, student internships, academic exchanges, workshops, seminars, and innovation projects in green building materials, advanced construction technologies, and cost management solutions.

Universiti Teknologi Malaysia (UTM) is Malaysia’s premier university for engineering, science, and technology, committed to building partnerships that enrich research output and provide students with real-world learning opportunities. The collaboration with CDL Academy exemplifies UTM’s efforts to equip graduates with the skills and experience needed to contribute effectively to the nation’s development.

Since its inception in 2019, CDL Academy has delivered over 100 seminars and learning engagements, benefiting more than 10,000 participants across the construction and engineering ecosystem. The collaboration with UTM expands these efforts, supporting the development of industry-ready graduates and addressing emerging needs in sustainable construction and advanced building technologies.

The MoU will be in effect for three years, with opportunities for renewal. Coordinators from both parties will oversee programme development to ensure measurable outcomes for students, researchers, and the construction industry.
Hashtag: #YTLCement, #CDLAcademy, #UTM, #ESG, #Sustainability, #Construction, #SustainableConstruction


The issuer is solely responsible for the content of this announcement.

CDL Academy Sdn Bhd

CDL Academy Sdn. Bhd. is the professional learning and development platform of the YTL Cement Group, established to support training and talent development within the construction industry. CDL Academy focuses on developing well-trained, industry-ready professionals through structured training and practical knowledge-sharing.

Beyond technical disciplines, CDL Academy serves as a hub for knowledge exchange, innovation and collaboration. It brings together practitioners, academics and universities, as well as industry leaders, industry associations and governing bodies through training programmes, seminars, workshops and strategic partnerships.

Through its commitment to quality education and best-practice sharing, CDL Academy aims to contribute to strengthening industry talent pipelines, supporting university–industry collaboration, and supporting the long-term advancement and sustainability of the construction ecosystem.

Universiti Teknologi Malaysia (UTM)

Universiti Teknologi Malaysia (UTM) is a premier public research university in Malaysia, specialising in engineering, science and technology. Located in Johor Bahru and with a campus in Kuala Lumpur, UTM is committed to producing globally competitive graduates and advancing cutting-edge research that addresses national and global challenges.

1...1,3741,3751,376...6,562Page 1,375 of 6,562